Exclusive: Royalty Pharma considers sweetened deal
Post# of 28533
Posted On: 04/12/2013 1:30:04 AM
Exclusive: Royalty Pharma considers sweetened deal for Elan - sources By Jessica Toonkel NEW YORK (Reuters) - Investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug Tysabri hits certain sales milestones, two people familiar with the matter said on Thursday. Royalty made its indicative approach, worth $11 per Elan share, in February, hoping to add rights to royalty payments for Tysabri worth hundreds of millions of dollars. ...
(0)
(0)
test
Scroll down for more posts ▼